Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Self-Healing Hydrogels for Material-Assisted Cell therapy in Osteoarthritis

Project description

Enhanced cell therapy for osteoarthritis

Osteoarthritis, a painful condition, affects the protective cartilage providing a smooth and slippery interface at bone joints. This cartilage gradually deteriorates, leaving bone to rub on bone. Intra-articular injections of multipotent stem cells have shown the most promise in treating the disease. However, the physiological saline in which the cells are delivered to the joints has not adequately fostered successful transplantation. The EU-funded project BABHY-CART is providing a friendlier microenvironment for the cells. It will mimic their natural environment, encouraging them to thrive and release anti-osteoarthritic factors in vivo.

Objective

Osteoarthritis (OA) is an incurable and painful disease. Over 70 million Europeans are currently affected by OA – a number that is set to increase with aging population and prevalence of obesity. To date, no clinically-efficient therapy exists to treat this socioeconomically debilitating disease. In this context, innovative regenerative therapies for joints are a pressing medical challenge.

Intraarticular mesenchymal stromal cell (MSC) injections hold the great promise of stopping and reversing age-associated inflammation and degeneration of joints by providing the necessary trophic factors to mitigate immune responses. However, translational progress using conventional cell delivery (saline) has been seriously hampered by the limited control over cell survival, location and fate in damaged joints. It is now common knowledge that cell microenvironment plays a crucial role in the success of cell transplantation; and appropriate synthetic matrix design is key to success.

To address challenges in intraarticular MSC-based immunomodulation strategies, we have envisioned an original hydrogel-assisted cell therapy. In this strategy, an injectable hyaluronic acid (HA)-based hydrogel with long-lasting viscoelastic properties will allow MSC encapsulation and cytoprotection, ensuring the production of anti-OA soluble factors in vivo. To best mimic synovial environment and support MSCs in vivo, we will synthesize a novel boronic acid-based, self-healing HA hydrogel with unique properties of injectability, stability and fast relaxation under mechanical load.

After carefully characterizing the physicochemical properties of this new class of biomaterials, we will investigate the effects of cell encapsulation on adipose stromal cell (ASC) survival, morphology and factor secretion. Then, the preclinical efficacy of intraarticular injections of cell-loaded, self-healing hydrogels will be confirmed in two complementary OA mice models.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 122 677,66
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 122 677,67

Participants (1)